JP2022546717A5 - - Google Patents
Info
- Publication number
- JP2022546717A5 JP2022546717A5 JP2022514513A JP2022514513A JP2022546717A5 JP 2022546717 A5 JP2022546717 A5 JP 2022546717A5 JP 2022514513 A JP2022514513 A JP 2022514513A JP 2022514513 A JP2022514513 A JP 2022514513A JP 2022546717 A5 JP2022546717 A5 JP 2022546717A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- deficiency
- tautomer
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1912674.7 | 2019-09-04 | ||
| GBGB1912674.7A GB201912674D0 (en) | 2019-09-04 | 2019-09-04 | Novel compounds |
| PCT/EP2020/074540 WO2021043870A1 (en) | 2019-09-04 | 2020-09-03 | Substituted cyanopyrrolidines with activity as usp30 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546717A JP2022546717A (ja) | 2022-11-07 |
| JP2022546717A5 true JP2022546717A5 (enExample) | 2023-09-11 |
Family
ID=68207049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514513A Ceased JP2022546717A (ja) | 2019-09-04 | 2020-09-03 | Ｕｓｐ３０阻害剤としての活性を有する置換シアノピロリジン類 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220315572A1 (enExample) |
| EP (1) | EP4025573B9 (enExample) |
| JP (1) | JP2022546717A (enExample) |
| KR (1) | KR20220054867A (enExample) |
| CN (1) | CN114341133B (enExample) |
| AU (1) | AU2020340527A1 (enExample) |
| BR (1) | BR112022003527A2 (enExample) |
| CA (1) | CA3146040A1 (enExample) |
| CO (1) | CO2022003608A2 (enExample) |
| GB (1) | GB201912674D0 (enExample) |
| IL (1) | IL290929B2 (enExample) |
| MX (1) | MX2022002686A (enExample) |
| WO (1) | WO2021043870A1 (enExample) |
| ZA (1) | ZA202203775B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| MX2022012578A (es) | 2020-04-08 | 2022-11-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| KR20230016674A (ko) | 2020-05-28 | 2023-02-02 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체 |
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| EP4547247A4 (en) * | 2022-06-30 | 2026-08-12 | Dana Farber Cancer Inst Inc | DESUBIQUITINASE INHIBITORS AND THEIR METHODS OF USE |
| KR20240132148A (ko) * | 2023-02-24 | 2024-09-03 | 연세대학교 산학협력단 | 인덴 유도체를 유효성분으로 포함하는 섬유화의 예방 또는 치료용 조성물 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| GB202500610D0 (en) | 2025-01-16 | 2025-03-05 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| UY31771A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| UY31770A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| JP6612751B2 (ja) | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| EP3193609A4 (en) * | 2014-09-10 | 2018-02-28 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| LT3277677T (lt) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) * | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| AU2018346597B2 (en) * | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP3837262B1 (en) | 2018-08-14 | 2026-06-17 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| KR20230016674A (ko) * | 2020-05-28 | 2023-02-02 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체 |
-
2019
- 2019-09-04 GB GBGB1912674.7A patent/GB201912674D0/en not_active Ceased
-
2020
- 2020-09-03 EP EP20771779.4A patent/EP4025573B9/en active Active
- 2020-09-03 US US17/639,015 patent/US20220315572A1/en not_active Abandoned
- 2020-09-03 KR KR1020227010882A patent/KR20220054867A/ko not_active Withdrawn
- 2020-09-03 AU AU2020340527A patent/AU2020340527A1/en not_active Abandoned
- 2020-09-03 JP JP2022514513A patent/JP2022546717A/ja not_active Ceased
- 2020-09-03 CA CA3146040A patent/CA3146040A1/en active Pending
- 2020-09-03 BR BR112022003527A patent/BR112022003527A2/pt unknown
- 2020-09-03 MX MX2022002686A patent/MX2022002686A/es unknown
- 2020-09-03 WO PCT/EP2020/074540 patent/WO2021043870A1/en not_active Ceased
- 2020-09-03 IL IL290929A patent/IL290929B2/en unknown
- 2020-09-03 CN CN202080061743.3A patent/CN114341133B/zh active Active
-
2022
- 2022-03-25 CO CONC2022/0003608A patent/CO2022003608A2/es unknown
- 2022-04-01 ZA ZA2022/03775A patent/ZA202203775B/en unknown